IPO pricing is imminent — typically 1-2 business days after effectiveness. Watch for the final IPO price and first-day trading performance. The $11-$13 range and 3.3M share base suggest a ~$40M gross raise for a pre-commercial biotech; post-IPO float and lockup terms will determine near-term liquidity.
Price Chart
Executive Summary
The SEC declared effective Retension Pharmaceuticals' S-1 registration statement for its initial public offering of 3,300,000 shares of common stock. The IPO is expected to price between $11.00 and $13.00 per share, with shares to list on Nasdaq under ticker RTSN. Effectiveness clears the final regulatory hurdle for the company to begin trading, likely within 1-2 days.
Key Facts
- IPO of 3,300,000 shares of common stock declared effective on October 8, 2026
- Expected price range: $11.00 to $13.00 per share
- Underwriters granted a 30-day option to purchase up to 495,000 additional shares
- Shares to list on Nasdaq Capital Market under ticker RTSN
- Underwriters: Leerink Partners, Guggenheim Securities, Oppenheimer & Co., Titan Partners
Financial Impact
IPO proceeds to the company before expenses at midpoint of range ($12.00/share) would be approximately $39.6 million from the base offering, plus up to $5.94 million from the overallotment option
Risk Factors
- IPO pricing below the indicated range or delayed due to market conditions
- Post-IPO dilution from the overallotment option and existing stock plans
- Pre-revenue biotech with no approved products — clinical and regulatory risk
Investment Themes
Documents Analyzed
This report is based on 3 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| EFFECT Filing (Primary) | 9999999995-26-003189 |
| Document: 9999999995-26-003189-index.html | 9999999995-26-003189 |
| Document: 9999999995-26-003189.txt | 9999999995-26-003189 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 22, 2026 4d ago | 8-K | $15.25 | awaiting T+5 | — | $14.24 (−6.62%) |
Oct 16, 2026 10d ago | SC 13G | $16.33 $14.65 | ▼ −10.29% | ▼ −10.14% | $14.24 (−12.80%) |
Oct 16, 2026 10d ago | SC 13G | $14.07 $15.25 | ▲ +8.39% | ▲ +8.82% | $14.24 (+1.21%) |
Oct 15, 2026 11d ago | SC 13G | $12.21 $15.50 | ▲ +26.95% | ▲ +27.96% | $14.24 (+16.63%) |
Oct 14, 2026 12d ago | SC 13D | $12.21 $15.50 | ▲ +26.95% | ▲ +27.96% | $14.24 (+16.63%) |
Oct 13, 2026 13d ago | Insider Cluster | $11.64 $15.00 | ▲ +28.87% | ▲ +28.41% | $14.24 (+22.34%) |
Oct 13, 2026 13d ago | 3 | $11.64 $15.00 | ▲ +28.87% | ▲ +28.41% | $14.24 (+22.34%) |
Oct 9, 2026 17d ago | 424B4 | $11.32 $16.33 | ▲ +44.26% | ▲ +45.75% | $14.24 (+25.80%) |
Oct 9, 2026 18d ago | EFFECT | $10.53 $14.07 | ▲ +33.62% | ▲ +35.59% | $14.24 (+35.23%) |
Oct 8, 2026 18d ago | 3 | $10.53 $14.07 | ▲ +33.62% | ▲ +35.59% | $14.24 (+35.23%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers